Navigation Links
DrugRisks News Update: Bayer Loses Yaz Patent as Blood Clot Settlements Continue
Date:4/26/2013

Chicago, IL (PRWEB) April 26, 2013

The birth control safety advocates at DrugRisks.com have added new information to the site for women using the contraceptives Yaz or Yasmin. A court recently ordered that Bayer no longer holds a patent on the drugs as the company continues to settle claims from patients alleging blood clot injuries**.

DrugRisks was created to give patients taking popular prescription drugs like Yaz and Yasmin the latest warnings, recalls, studies and legal news. With access to clear information, patients can discuss side effect concerns with their doctor and decide if they need legal advice.

The British Medical Journal and FDA have cautioned that birth control pills containing drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%*.

With a growing number of patients filing a Yaz lawsuit alleging blood clot injuries, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

Now, DrugRisks has added information showing the U.S. Circuit Court of Appeals for Washington last week ruled Bayer’s patent on Yaz, which was set to expire in 2014, is no longer valid**. This will allows competitors Actavis, Sandoz and Lupin to continue selling their generic versions of the drug**.

Bayer’s latest financial reports show the company has spent nearly $1 billion to settle around 4,800 claims alleging Yaz blood clots, and will continue to evaluate new claims for settlement on a case-by-case basis***.

Lawyers are still helping those affected file a claim. Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to contact the DrugRisks Center or speak with a lawyer about their legal options.

Due to the specialized nature of federal MDL drug injury cases, DrugRisks cautions that patients should seek a lawyer with experience in this litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

Visit http://www.DrugRisks.com today for more information on the research, Yaz side effects and litigation news related to Yaz or Yasmin, or to speak with a lawyer.

*British Medical Journal, October 25, 2011, University of Copenhagen; FDA, October 27, 2011, "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints"
**businessweek.com/news/2013-04-16/bayer-patent-on-yaz-birth-control-pill-ruled-invalid
***Bayer 2012 Annual Report, Consolidated Financial Statement, Legal Notes, February 28, 2013

Read the full story at http://www.prweb.com/releases/yaz-side-effects/2013-settlement-news/prweb10662368.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Adds Update From Court Ordering Mediation of Stryker Hip Lawsuits
2. DrugRisks Update: Federal Court Schedules First Mirena Lawsuit Hearing
3. DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
4. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
5. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
6. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
7. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
8. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
9. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
10. Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Some CasesDismissed from Consolidated Litigation
11. DrugRisk Update: Court Asks for Pradaxa Lawsuit Test Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at the ... The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will feature ...
(Date:1/23/2017)... ... 2017 , ... "ProRandom is a set of camera tools that allow video editors to integrate ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , With ProRandom, ... video footage. ProRandom works by using a virtual camera to create the illusion of ...
(Date:1/23/2017)... ... January 23, 2017 , ... “The Inn at the Mill”: a story of love and ... quest to become happy and content. , “The Inn at the Mill” is the ... in Germany and Vermont and is now living in Berks County on Crow Hill. ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of ... Father. “Some Infallible Characteristics of Christ” is the creation of published author, Rev. Dr. ... Baptist Church for thirteen years, a preacher for over nineteen, a pastor for over ...
(Date:1/22/2017)... ... 2017 , ... "Photo Cloud allows FCPX users to add favorited photos to ... ease," said Christina Austin - CEO of Pixel Film Studios. , To begin, ... timeline. Presets include scenes with one, three, four or five focus points. There are ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , January 23, 2017 A new Transparency ... Market was valued at US$0.53 bn in 2013 and is ... strong 17.50% CAGR between 2014 and 2022. The title of the ... Size, Volume, Share, Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), ...
(Date:1/23/2017)... DIEGO and PALMA, Spain ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company ... that the first patient has been enrolled in ... lead candidate, SNF472, for the treatment of cardiovascular ... (HD). Most ESRD patients, in the ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab (Hospital, ... HIV/AIDS etc.), Forecast to 2022" report to their offering. ... US ... clinical lab testing, which has evolved as a major source ...
Breaking Medicine Technology: